John Tucker Appointed CEO of scPharmaceuticals

scPharmaceuticals announced that John Tucker has been appointed as president and CEO and also elected to the board of directors effective immediately.

Mr. Tucker holds a BA from Plymouth State College and an MBA from New Hampshire College and has over 25 years of experience in the pharmaceutical industry. Prior to joining scPharmaceuticals, he served many profiles :-

• CEO at Alcresta – where he led regulatory and financing strategies resulting in Alcresta’s first product approval and product launch.
• Senior VP and chief commercial officer at Incline Therapeutics, where he developed and drove the overall commercial strategy in support of the company’s lead product, IONSYS, resulting in a $390 million purchase of Incline by The Medicines Company.
• Senior VP, commercial operations at AMAG Pharmaceuticals, where he was responsible for all sales and marketing activities for the company.
• President of U.S. operations at Basilea Pharmaceuticals, where he developed the strategy and organization for the planned launch of a hospital-focused product and led the company’s commercial development team.
• VP, sales and marketing at Indevus Pharmaceuticals
•  Retail-based sales and marketing positions in his earlier career at Ortho-McNeil Pharmaceuticals, ALZA Corporation, VIVUS and UCB Pharma.

scPharmaceuticals board member, Jack Khattar said that John has both the strong leadership skills and the business expertise required to successfully position scPharmaceuticals as a leading biopharmaceutical company. John’s experience building commercial-ready infrastructures in both private and public companies, as well as developing new markets, will be enormously beneficial to scPharmaceuticals as they advance their lead program and continue the transition from a research and development company to a commercial-stage organization.